Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain Xiaowei.

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD

Psoriasis and suicidality: A systematic review and meta-analysis

Effectiveness of low-level laser therapy in lichen planopilaris

Baldness reversed by chemotherapy

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β-adrenergic blocker Chia-Chi Hsu, MD,

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Pain and nonmelanoma skin cancer in transplant patients

Brachioradial pruritus: A trigger for generalization of itch

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain Xiaowei.

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta- analysis of randomized controlled trials Ashar Dhana, MBBCh, MPH,

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Recalcitrant prurigo nodularis treated successfully with dupilumab

Hugh Gloster, MD, Chesahna Kindred, MBA

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study Hyun Jeong Ju, MD, Ki-Jo Kim, MD, PhD,

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Blake R. Zelickson, MD, PhD, Leonard H. Goldberg, MD, Marc K

Derek Y. Hsu, BA, Kenneth Gordon, MD, Jonathan I

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Ethnic differences and comorbidities of 909 prurigo nodularis patients

The JAAD adopts the CONSORT statement

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD, Joe Hirman, PhD, Andrew J. Perlman, MD, PhD, Elke Weisshaar, MD, Martin Metz, MD, Thomas A. Luger, MD Journal of the American Academy of Dermatology Volume 80, Issue 5, Pages 1395-1402 (May 2019) DOI: 10.1016/j.jaad.2019.01.052 Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Changes from baseline over time. A, Percentage change from baseline in mean average itch visual analog scale (VAS) score at weeks 2, 4, and 8. Asterisks indicate P < .05 for the mean difference of serlopitant versus placebo. B, Forest plot of average intensity with standard error (SE) for average itch VAS score change from baseline at weeks 4 and 8, by subgroup (intention-to-treat population). Journal of the American Academy of Dermatology 2019 80, 1395-1402DOI: (10.1016/j.jaad.2019.01.052) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Changes from baseline over time. Percentage change from baseline in least squares mean average itch numeric rating scale (NRS) score at weeks 2, 4, and 8. Asterisk indicates P ≤ .05 for the mean difference of serlopitant versus placebo. SE, Standard error. Journal of the American Academy of Dermatology 2019 80, 1395-1402DOI: (10.1016/j.jaad.2019.01.052) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions